# Virbac SA/ADR Virbac SA/ADR is a Publicly Traded Company based in Carros, France. ## Overview - **Organization type:** Publicly Traded Company - **Headquarters:** Carros, France - **Region:** Europe - **Address:** Carros, France - **Founded:** 1968 - **Assets under management:** Undisclosed - **Website:** virbac.com ## Regulatory record - **Reports private funds:** No ## About Virbac was founded in 1968 by veterinarian Pierre-Richard Dick in Carros, near Nice, France. The company originally focused on developing veterinary pharmaceuticals for companion animals and livestock, a niche it has maintained as its core. Today Virbac is publicly traded on Euronext Paris (EPA: VIRP) and remains under the founding family's influence through a controlling stake held by the Dick family (per public filings). The firm's strategy centers on prescription and over-the-counter animal-health products, including vaccines, parasiticides, anti-infectives, and dermatological treatments. It also operates a diagnostics division. Virbac's geographic footprint spans Europe, North America, Latin America, Asia-Pacific, Africa, and the Middle East. Key markets include the United States, France, Australia, and Brazil. In 2024, Virbac acquired the U.S. animal-health business of Bimeda, expanding its presence in the North American market (per Virbac press release, 2024). As of 2024, Virbac employed approximately 5,500 people worldwide. The company has R&D centers in France, the U.S., and Australia. Adjacent to its pharmaceutical business, Virbac operates a veterinary diagnostics arm. A recent operational event: In March 2025, Virbac announced the appointment of Sébastien Huron as CFO, succeeding Jérôme Ponte (per Virbac announcement, March 2025). A structural differentiator: Virbac is one of the few independent, pure-play animal-health companies of significant scale that is not a division of a larger human-pharma conglomerate. Its founding-family control provides a long-term strategic horizon distinct from the quarterly focus typical of widely held pharma companies. ## Sectors - Healthcare Services - Animal Health ## People - Pierre Dick — Chief Executive Officer - Sébastien Huron — Chief Financial Officer ## Questions ### Who controls Virbac after going public? The founding Dick family retains a controlling stake in Virbac through a holding company. While the firm is publicly traded on Euronext Paris, the family's voting power and board representation ensure continued strategic influence (per public filings). ### What is Virbac's core business vs. larger animal-health competitors? Virbac is a pure-play animal-health company, unlike Zoetis, Elanco, or Merck Animal Health which are divisions of diversified pharmaceutical conglomerates. Virbac focuses specifically on veterinary drugs, vaccines, and diagnostics, with a particular emphasis on companion animals (dogs and cats) and livestock. This specialization allows it to compete effectively in niche therapeutic areas. ### Does Virbac have a significant presence in the U.S. market? Yes, the United States is one of Virbac's largest markets. The company has a subsidiary, Virbac Corporation, based in Fort Worth, Texas. In 2024, Virbac expanded its U.S. footprint by acquiring Bimeda's U.S. animal-health business (per Virbac press release, 2024). ### What are Virbac's major product categories? Virbac's product portfolio includes vaccines (for dogs, cats, horses, and livestock), parasiticides (such as flea and tick treatments), anti-infectives, dermatological products, and nutritional supplements. The company also produces diagnostic kits and imaging products for veterinary use. ### How does Virbac approach research and development? Virbac invests approximately 5% of its annual revenue into R&D. Its R&D facilities are located in France, the United States, and Australia. The company focuses on developing novel vaccines and therapeutic solutions for under-served animal diseases, often in collaboration with academic institutions and other research organizations. ### What is the geographic breakdown of Virbac's revenue? Virbac generates revenue across all major regions. In its 2023 annual report, the firm reported approximately 34% of sales in Europe, 25% in the Americas, 20% in Asia-Pacific, and 21% in Africa and the Middle East. The U.S. and France are its largest individual country markets. ## Related profiles - [Palomino Laboratories Inc.](https://altss.com/profile/palomino-laboratories-inc) - [LianBio](https://altss.com/profile/lianbio) --- Last updated: 2026-06-03T20:00:00.000Z Canonical page: https://altss.com/profile/virbac-saadr Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology